Ingrid T Katz1,2,3, Nicholas Musinguzi4, Kathleen Bell5, Anna Cross6, Mwebesa B Bwana4, Gideon Amanyire4, Stephen Asiimwe4,7, Catherine Orrell6, David R Bangsberg8, Jessica E Haberer2,5. 1. Department of Medicine, Brigham and Women's Hospital, Boston, MA. 2. Harvard Medical School, Boston, MA. 3. Harvard Global Health Institute, Cambridge, MA. 4. Mbarara University of Science and Technology, Mbarara, Uganda. 5. Massachusetts General Hospital Center for Global Health, Boston, MA. 6. Desmond Tutu HIV Foundation, University of Cape Town Medical School, Cape Town, South Africa. 7. Kabwohe Clinical Research Center, Kabwohe, Uganda; and. 8. Oregon Health and Science University-Portland State University School of Public Health, Portland, OR.
Abstract
BACKGROUND: Adoption of "Treat All" policies has increased antiretroviral therapy (ART) initiation in sub-Saharan Africa; however, unexplained early losses continue to occur. More information is needed to understand why treatment discontinuation continues at this vulnerable stage in care. METHODS: The Monitoring Early Treatment Adherence Study involved a prospective observational cohort of individuals initiating ART at early-stage versus late-stage disease in South Africa and Uganda. Surveys and HIV-1 RNA levels were performed at baseline, 6, and 12 months, with adherence monitored electronically. This analysis included nonpregnant participants in the first 6 months of follow-up; demographic and clinical factors were compared across groups with χ2, univariable, and multivariable models. RESULTS: Of 669 eligible participants, 91 (14%) showed early gaps of ≥30 days in ART use (22% in South Africa and 6% in Uganda) with the median time to gap of 77 days (interquartile range: 43-101) and 87 days (74, 105), respectively. Although 71 (78%) ultimately resumed care, having an early gap was still significantly associated with detectable viremia at 6 months (P ≤ 0.01). Multivariable modeling, restricted to South Africa, found secondary education and higher physical health score protected against early gaps [adjusted odds ratio (aOR) 0.4, 95% confidence interval (CI): 0.2 to 0.8 and (aOR 0.93, 95% CI: 0.9 to 1.0), respectively]. Participants reporting clinics as "too far" had double the odds of early gaps (aOR 2.2: 95% CI: 1.2 to 4.1). DISCUSSION: Early gaps in ART persist, resulting in higher odds of detectable viremia, particularly in South Africa. Interventions targeting health management and access to care are critical to reducing early gaps.
BACKGROUND: Adoption of "Treat All" policies has increased antiretroviral therapy (ART) initiation in sub-Saharan Africa; however, unexplained early losses continue to occur. More information is needed to understand why treatment discontinuation continues at this vulnerable stage in care. METHODS: The Monitoring Early Treatment Adherence Study involved a prospective observational cohort of individuals initiating ART at early-stage versus late-stage disease in South Africa and Uganda. Surveys and HIV-1 RNA levels were performed at baseline, 6, and 12 months, with adherence monitored electronically. This analysis included nonpregnant participants in the first 6 months of follow-up; demographic and clinical factors were compared across groups with χ2, univariable, and multivariable models. RESULTS: Of 669 eligible participants, 91 (14%) showed early gaps of ≥30 days in ART use (22% in South Africa and 6% in Uganda) with the median time to gap of 77 days (interquartile range: 43-101) and 87 days (74, 105), respectively. Although 71 (78%) ultimately resumed care, having an early gap was still significantly associated with detectable viremia at 6 months (P ≤ 0.01). Multivariable modeling, restricted to South Africa, found secondary education and higher physical health score protected against early gaps [adjusted odds ratio (aOR) 0.4, 95% confidence interval (CI): 0.2 to 0.8 and (aOR 0.93, 95% CI: 0.9 to 1.0), respectively]. Participants reporting clinics as "too far" had double the odds of early gaps (aOR 2.2: 95% CI: 1.2 to 4.1). DISCUSSION: Early gaps in ART persist, resulting in higher odds of detectable viremia, particularly in South Africa. Interventions targeting health management and access to care are critical to reducing early gaps.
Authors: Edwin Wouters; Wim Van Damme; Dingie van Rensburg; Caroline Masquillier; Herman Meulemans Journal: BMC Health Serv Res Date: 2012-07-09 Impact factor: 2.655
Authors: Dorothy E Dow; Blandina T Mmbaga; Elizabeth L Turner; John A Gallis; Zachary J Tabb; Coleen K Cunningham; Karen E O'Donnell Journal: AIDS Care Date: 2019-01-09
Authors: Martin W G Brinkhof; François Dabis; Landon Myer; David R Bangsberg; Andrew Boulle; Denis Nash; Mauro Schechter; Christian Laurent; Olivia Keiser; Margaret May; Eduardo Sprinz; Matthias Egger; Xavier Anglaret Journal: Bull World Health Organ Date: 2008-07 Impact factor: 9.408
Authors: Valerie A Earnshaw; Laura M Bogart; Ingrid Courtney; Holly Zanoni; David R Bangsberg; Catherine Orrell; Kathy Goggin; Ingrid T Katz Journal: AIDS Behav Date: 2018-08
Authors: Jacob Bor; Matthew P Fox; Sydney Rosen; Atheendar Venkataramani; Frank Tanser; Deenan Pillay; Till Bärnighausen Journal: PLoS Med Date: 2017-11-28 Impact factor: 11.613
Authors: Matthew P Fox; Sophie Pascoe; Amy N Huber; Joshua Murphy; Mokgadi Phokojoe; Marelize Gorgens; Sydney Rosen; David Wilson; Yogan Pillay; Nicole Fraser-Hurt Journal: PLoS Med Date: 2019-07-23 Impact factor: 11.069